Industry updates from the field of stem cell research and regenerative medicine in January 2022-Reference-Cited by-同舟云学术

Industry updates from the field of stem cell research and regenerative medicine in January 2022

Published:2022-05 Issue:5 Volume:17 Page:245-253
ISSN:1746-0751
Container-title:Regenerative Medicine
language:en
Short-container-title:Regenerative Medicine

Author:

Ilic Dusko¹^ORCID,Liovic Mirjana²^ORCID

Affiliation:

1. Department of Women & Children’s Health, Stem Cell Laboratories, Guy’s Assisted Conception Unit, Faculty of Life Sciences & Medicine, King’s College London, London, SE1 9RT, UK

2. Medical Center for Molecular Biology, Faculty of Medicine, University of Ljubljana, Ljubljana, 1000, Slovenia

Abstract

Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from non academic institutions in January 2022.

Publisher

Future Medicine Ltd

Subject

Embryology,Biomedical Engineering

Link

https://www.futuremedicine.com/doi/pdf/10.2217/rme-2022-0039

Reference35 articles.

1. BusinessWire. Bayer and Mammoth Biosciences to collaborate on novel gene editing technology (2022). www.businesswire.com/news/home/20220109005059/en/Bayer-and-Mammoth-Biosciences-to-Collaborate-on-Novel-Gene-Editing-Technology

2. Bristol-Myers Squibb. Century Therapeutics and Bristol Myers Squibb enter into a strategic collaboration to develop iPSC-derived allogeneic cell therapies (2022). https://news.bms.com/news/corporate-financial/2022/Century-Therapeutics-and-Bristol-Myers-Squibb-Enter-into-a-Strategic-Collaboration-to-Develop-iPSC-derived-Allogeneic-Cell-Therapies/default.aspx 19

3. BusinessWire. GC Cell Inks first licensing agreement for Immuncell-LC® with Rivaara Immune Private Limited in India (2022). www.businesswire.com/news/home/20220103005504/en/GC-Cell-Inks-First-Licensing-Agreement-for-Immuncell-LC%C2%AE-With-Rivaara-Immune-Private-Limited-in-India

4. Sana Biotechnology. Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics announce non-exclusive license agreement for clinically validated BCMA CAR construct (2022). https://ir.sana.com/node/7221/pdf

5. Sana Biotechnology. Sana Biotechnology obtains exclusive license from National Institutes of Health for CD22 CAR construct (2022). https://ir.sana.com/node/7231/pdf

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ready, set, regenerate! A retrospect of 2022;Regenerative Medicine;2023-01